| Name | Title | Contact Details |
|---|
Feed the world without ruining it.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
BMC helps customers run and reinvent their businesses with open, scalable, and modular solutions to complex IT problems.
Pitney Bowes is a global technology company most known for its postage meters and other mailing equipment and services, and with recent expansions, into global e-commerce, software, and other technologies.